CCR1 and neoplasm: As a clinically applicable CCR1 inhibitor, we previously established a novel neutralizing anti-CCR1 mAb, KM5908, which was proven to suppress CCR1+ myeloid cell accumulation and tumor progression in preclinical mouse models [13].